|
UPF3A expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 1.62581059726108E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.222800053024E-13 |
| Normal-vs-Stage2 |
9.94959999944811E-07 |
| Normal-vs-Stage3 |
4.16777723444284E-13 |
| Normal-vs-Stage4 |
5.81289461010215E-11 |
| Stage1-vs-Stage2 |
9.297200E-01 |
| Stage1-vs-Stage3 |
3.548000E-02 |
| Stage1-vs-Stage4 |
5.500300E-02 |
| Stage2-vs-Stage3 |
1.556840E-01 |
| Stage2-vs-Stage4 |
1.332560E-01 |
| Stage3-vs-Stage4 |
7.926200E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.33066907387547E-16 |
| Normal-vs-AfricanAmerican |
8.623200E-03 |
| Normal-vs-Asian |
9.42410000037697E-07 |
| Caucasian-vs-AfricanAmerican |
7.378500E-03 |
| Caucasian-vs-Asian |
9.720500E-02 |
| AfricanAmerican-vs-Asian |
2.087600E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
6.09345907065517E-12 |
| Normal-vs-Female |
1.63702384980979E-12 |
| Male-vs-Female |
9.566400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.30158123063029E-12 |
| Normal-vs-Age(41-60Yrs) |
2.18369766713522E-11 |
| Normal-vs-Age(61-80Yrs) |
5.85953507936665E-12 |
| Normal-vs-Age(81-100Yrs) |
3.92550000000158E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
9.765600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
1.972400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.978300E-02 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
2.310600E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
1.444760E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.820400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.163780E-04 |
| Classical-VS-Follicular |
1.181370E-01 |
| Classical-VS-Other |
5.979000E-01 |
| Classical-VS-Normal |
1.23809995589141E-09 |
| Tall-VS-Follicular |
2.20179999999015E-06 |
| Tall-VS-Other |
4.800000E-03 |
| Tall-VS-Normal |
2.54241072639161E-14 |
| Follicular-VS-Other |
9.137600E-01 |
| Follicular-VS-Normal |
1.91032999999896E-05 |
| Other-VS-Normal |
2.380300E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.04964950462272E-12 |
| Normal-vs-N1 |
1.03090003200634E-09 |
| N0-vs-N1 |
3.719600E-01 |
|
|
